6-Amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,3-diazinane-2,4-dione

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 6-Amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,3-diazinane-2,4-dione
• 英文别名: 6-amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,3-diazinane-2,4-dione
• 化学式: C₁₀H₁₇N₃O₅
• 分子量: 259.26
• InChiKey: FTCOOFPNIPYKKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• USES OF DIHYDRO BASES
  申请人：Massachusetts Institute of Technology

  公开号：US20140206639A1

  公开（公告）日：2014-07-24

  The present invention provides pharmaceutical compositions comprising a dihydro base described herein (e.g., compound DHdC). The dihydro base may show multiple tautomerism and may increase mutation of an RNA and/or DNA of a virus or cancer cell. The dihydro base may be used to reduce DNA methylation (e.g., in a cancer cell). The present invention also provides kits including the inventive pharmaceutical compositions and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis C) or cancer using the pharmaceutical compositions or kits.

  本发明提供了含有本文描述的二氢基（例如，化合物DHdC）的药物组合物。该二氢基可能显示多重互变异构体，并可能增加病毒或癌细胞的RNA和/或DNA的突变。该二氢基可用于减少DNA甲基化（例如，在癌细胞中）。本发明还提供包括创新药物组合物的试剂盒和使用这些药物组合物或试剂盒治疗病毒感染（例如流感、HIV感染或丙型肝炎）或癌症的方法。
• US9283242B2
  申请人：——

  公开号：US9283242B2

  公开（公告）日：2016-03-15
• [EN] USES OF DIHYDRO BASES<br/>[FR] UTILISATIONS DE BASES DIHYDRO
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2014116755A1

  公开（公告）日：2014-07-31

  The present invention provides pharmaceutical compositions comprising a dihydro base described herein (e.g., compound DHdC). The dihydro base may show multiple tautomerism and may increase mutation of an RNA and/or DNA of a virus or cancer cell. The dihydro base may be used to reduce DNA methylation (e.g., in a cancer cell). The present invention also provides kits including the inventive pharmaceutical compositions and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis C) or cancer using the pharmaceutical compositions or kits.